A CBD product page translated correctly into German, French, and Spanish can still be non-compliant in two of those three markets. The words are right. The regulatory category behind them is not.
Cannabis localization in Europe gets treated as a language problem — pick the right words, adjust the tone, ship the page. What gets missed is that every EU regulator names and regulates the same compound differently. A linguistically flawless translation built on the wrong regulatory category creates a compliance problem, not a communication one.
The Same Compound, Different Regulatory Names
CBD does not mean the same thing to AEMPS, BfArM, MHRA, and EFSA. Spain’s AEMPS regulates medicinal cannabis preparations under Real Decreto 903/2025. The official term is “preparados estandarizados de cannabis” — a hospital-dispensed category tied to its own AEMPS registration process.
Germany’s BfArM works from a medical cannabis framework where reform (the MedCanG amendment) has, as of August 2026, been stalled in parliamentary committee for months. That means current terminology stays in force longer than anyone planned for.
In Great Britain, CBD food products follow the FSA’s post-Brexit novel food framework — on a timeline separate from the EU’s EFSA evaluations. Medicinal cannabis products, however, fall under MHRA regulation. EFSA itself published a scientific opinion proposing a provisional safe intake level of approximately 2 mg/day for a 70 kg adult as part of its novel food risk assessment. That figure is not a legally binding limit. No CBD novel food application has yet completed the authorisation process.
Four different authorities. Four different vocabularies for the same molecule. A product page that says “CBD oil” in English can be translated word-for-word into Spanish and German and read fluently in both — while the regulatory basis for selling that product differs in each market it lands in.
What Real European Cannabis Markets Reveal About Localization
Vocabulary gaps show up fastest in the markets furthest along in regulating cannabis as a legal product. The Netherlands built its regulated cannabis pilot — officially the “Experiment gesloten coffeeshopketen” — around a closed supply chain running from licensed cultivation through to the coffeeshop counter. That supply chain has its own Dutch-language policy vocabulary for describing each link in the chain. A translation that renders those terms as generic English words for “cannabis supply” loses the specific legal structure the term is pointing to. Compliance documentation built on top of that translation stops matching the regulatory reality it describes.
Spain presents a different problem: a newly defined category, not an established one. Real Decreto 903/2025 introduced “preparados estandarizados de cannabis” as the official Spanish term for hospital-dispensed medicinal cannabis preparations, tied to a specific AEMPS registration process. There is no single equivalent English term. Translating it as generic “standardised cannabis preparations” drops the RD 903/2025 legal framework that gives the Spanish term its meaning.
Germany adds a third pattern: a vocabulary that hasn’t finished changing. The MedCanG reform, which would update prescribing and access rules for medical cannabis, has, as of August 2026, sat in parliamentary committee for months. Documentation written against the current framework has a shelf life nobody can currently predict.
Why Stopping at Grammar Creates Compliance Risk
Most localization budgets stop at the point where the text reads naturally in the target language. For a regulated product in a category that often feels unregulated, that’s the wrong stopping point.
A product page, a summary of product characteristics, a distributor agreement, or a customer notice can be grammatically flawless and still misrepresent the regulatory category a market’s authority actually uses. That gap turns a translation project into a compliance exposure the brand didn’t know it had.
This is the layer a generalist translation workflow structurally can’t cover: knowing that “CBD oil” needs a different regulatory frame in Spain than in the Netherlands, or that a term stable in English has three unstable equivalents across three EU markets. It requires tracking regulatory vocabulary the way a compliance team would, not the way a language pair would.
The Takeaway
The compound doesn’t change between Madrid, Berlin, Amsterdam, and London. The regulatory vocabulary around it does. It keeps changing on different schedules, in different directions, market by market.
A brand that treats cannabis localization in Europe as a single translation project, done once, is building compliance risk into its own expansion plan.
Which of your active EU markets still shares a glossary with your source-language documentation — and when did you last check?
This article is for informational purposes only and does not constitute legal advice. Cannabis regulations change rapidly — verify current requirements with qualified legal counsel before making compliance decisions.
Sources
- EFSA — Provisional safe level for cannabidiol as a novel food (Feb. 2026)
- BOE — Real Decreto 903/2025, de 7 de octubre
- Rijksoverheid (Netherlands) — Experiment gesloten coffeeshopketen
- Food Standards Agency (UK) — CBD and novel food
Recent Comments